Latest Breaking News On - Clin pharmacol - Page 4 : comparemela.com

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

Etanercept enbrelJ clin pharmacolPediatr rheumatolVan dijkhuizenChild health questionnairePediatric rheumatology collaborative study groupChildhood health assessment questionnaireAmerican college of rheumatologyInternational leagueRev dis primersRheumatology collaborative studyEnglj medCare resSyst pharmacolExp rheumatolAmerican college

How uncontrolled diabetes can damage your heart

Type 2 diabetes is strongly linked to heart disease, with studies showing that it is the leading cause of death among people with diabetes worldwide.

United statesVan gaalClin pharmacolColl cardiolEduc health promotNational institute of diabetesBody massNational instituteKidney diseasesDiabetes resHeart diseaseObes metabPi sunyer diabetes careRev clin pharmacolCurr atherosclerHigh blood pressure

4 Ways Type 2 diabetes can become a concern for people with diabetes

Type 2 diabetes can cause severe short-term and long-term complications, including kidney and nerve damage. Heart disease is the leading cause of death among people with type 2 diabetes.

United kingdomClin pharmacolEndocrinol lausanneVan gaalNational cohort of adultsNovo nordiskDiabetes unitedMellitus related all causeCardiovascular mortalityNational cohortIntj clinDiabetes resObes metabSunyer diabetes careRev clin pharmacolEconomic times news app

Adolescent Substance Use: Reasons for Optimism and Concern

"Although adolescent substance use is a topic that can be challenging for families and clinicians alike, data demonstrate that interventions during this time are effective for preventing, identifying, and reducing risky use."

United statesUniversity of washingtonCrotty alexanderJoshua resnickMental health comorbiditiesBoston medical centerBehavioral health clinicianInstitute for social researchCenters for diseaseLung injury response epidemiology surveillance taskWashington state prevention research subcommitteeSchool studentsLouisiana state university in shreveport dr yuleisBoston university chobanian avedisian school of medicineDrug administrationNational survey results on drug

Nemolizumab Monotherapy Successful in Prurigo Nodularis Patients Becoming Itch-Free

New late-breaking phase 3 data showed success with nemolizumab, an investigational drug designed for targeting IL-31 signaling and aimed at the underlying causes of the condition.

Clin pharmacolDermatol venereolNemolizumab monotherapyWorld congressLate breaking phasePublished julyEur acad dermatolExpert rev clin